The partnership gives each company non-exclusive access to the other's technology and may also include opportunities for transnational clinical trials.
The firms will partner on studies needed to support and secure US regulatory approval for the Elio tissue complete assay.
The companies initially expect to incorporate a CDx for Incyte's pemigatinib into Foundation Medicine's existing FDA-approved assay, FoundationOne CDx.
Roche Diagnostics CEO said that it seeks to continue generating cash from its current IVD businesses, in part to fund investments in digital diagnostics.
The two companies will initially collaborate on global commercialization of assays that have been developed by LabCorp and its Covance unit.
The companies said they plan to develop a number of tests, beginning with a CTC-based PD-L1 assay that measures both RNA and protein expression.
Natera and Qiagen have signed a 10-year agreement to develop cell-free DNA assays for use on Qiagen's GeneReader next-generation sequencing system.
Irish rare disease research center FutureNeuro is partnering with software vendor Congenica to bring sequencing to the point of care for genetic epilepsies.
In the longer term, the two firms plan to use PlexBio's multiplexing technology to develop a full menu of infectious disease assays.
Biocartis will help develop and commercialize Immunexpress' Septicyte test to run on the Idylla platform.